Tags

Type your tag names separated by a space and hit enter

Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients.
Gynecol Endocrinol 2012; 28(12):969-73GE

Abstract

Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism, chronic anovulation, polycystic ovaries at ultrasound evaluation, and quite frequently by insulin resistance or compensatory hyperinsulinemia. Attention has been given to the role of inositol-phosphoglycan (IPG) mediators of insulin action and growing evidences suggest that a deficiency of D-chiro-inositol (DCI) containing IPG might be at the basis of insulin resistance, frequent in PCOS patients. On such basis, we investigated the efficacy on insulin sensitivity and hormonal parameters of 8 weeks treatment with myo-inositol (MYO) (Inofert, ItalPharmaco, Milano, Italy) at the dosage of 2 g day in a group (n = 42) of obese PCOS patients,. After the treatment interval body mass index (BMI) and insulin resistance decreased together with luteinizing hormone (LH), LH/FSH and insulin. When subdividing the patients according to their fasting insulin levels, Group A (n = 15) insulin below 12 µU/ml and Group B (n = 27) insulin above 12 µU/ml, MYO treatment induced similar changes in both groups but only patients of Group B showed the significant decrease of both fasting insulin plasma levels (from 20.3 ± 1.8 to 12.9 ± 1.8 µU/ml, p < 0.00001) and of area under the curve (AUC) of insulin under oral glucose tolerance test (OGTT). In conclusion, our study supports the hypothesis that MYO administration is more effective in obese patients with high fasting insulin plasma levels.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Center for Gynecological Endocrinology, University of Modena and Reggio Emilia, Modena, Italy. algen@unimo.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

22612517

Citation

Genazzani, Alessandro D., et al. "Differential Insulin Response to Myo-inositol Administration in Obese Polycystic Ovary Syndrome Patients." Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, vol. 28, no. 12, 2012, pp. 969-73.
Genazzani AD, Prati A, Santagni S, et al. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecol Endocrinol. 2012;28(12):969-73.
Genazzani, A. D., Prati, A., Santagni, S., Ricchieri, F., Chierchia, E., Rattighieri, E., ... Artini, P. G. (2012). Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, 28(12), pp. 969-73. doi:10.3109/09513590.2012.685205.
Genazzani AD, et al. Differential Insulin Response to Myo-inositol Administration in Obese Polycystic Ovary Syndrome Patients. Gynecol Endocrinol. 2012;28(12):969-73. PubMed PMID: 22612517.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. AU - Genazzani,Alessandro D, AU - Prati,Alessia, AU - Santagni,Susanna, AU - Ricchieri,Federica, AU - Chierchia,Elisa, AU - Rattighieri,Erica, AU - Campedelli,Annalisa, AU - Simoncini,Tommaso, AU - Artini,Paolo G, Y1 - 2012/05/21/ PY - 2012/5/23/entrez PY - 2012/5/23/pubmed PY - 2013/4/30/medline SP - 969 EP - 73 JF - Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology JO - Gynecol. Endocrinol. VL - 28 IS - 12 N2 - Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism, chronic anovulation, polycystic ovaries at ultrasound evaluation, and quite frequently by insulin resistance or compensatory hyperinsulinemia. Attention has been given to the role of inositol-phosphoglycan (IPG) mediators of insulin action and growing evidences suggest that a deficiency of D-chiro-inositol (DCI) containing IPG might be at the basis of insulin resistance, frequent in PCOS patients. On such basis, we investigated the efficacy on insulin sensitivity and hormonal parameters of 8 weeks treatment with myo-inositol (MYO) (Inofert, ItalPharmaco, Milano, Italy) at the dosage of 2 g day in a group (n = 42) of obese PCOS patients,. After the treatment interval body mass index (BMI) and insulin resistance decreased together with luteinizing hormone (LH), LH/FSH and insulin. When subdividing the patients according to their fasting insulin levels, Group A (n = 15) insulin below 12 µU/ml and Group B (n = 27) insulin above 12 µU/ml, MYO treatment induced similar changes in both groups but only patients of Group B showed the significant decrease of both fasting insulin plasma levels (from 20.3 ± 1.8 to 12.9 ± 1.8 µU/ml, p < 0.00001) and of area under the curve (AUC) of insulin under oral glucose tolerance test (OGTT). In conclusion, our study supports the hypothesis that MYO administration is more effective in obese patients with high fasting insulin plasma levels. SN - 1473-0766 UR - https://www.unboundmedicine.com/medline/citation/22612517/Differential_insulin_response_to_myo_inositol_administration_in_obese_polycystic_ovary_syndrome_patients_ L2 - http://www.tandfonline.com/doi/full/10.3109/09513590.2012.685205 DB - PRIME DP - Unbound Medicine ER -